ATMP 2024 Conference Recordings

Opening Adress: Gisela Helenius, Anna Falk, Ulrika Ringdahl
Planning inspection of manufacture and clinics for FIH ATMP clinical trials: Gisela Helenius & Annika Baan – Sahlgrenska University Hospital (V)
Tissue establishment inspection of ATMP start material collection: Katarina Widell (V) – Läkemedelsverket
GMP inspections from an auditors perspective: Virve Reiman-Suijkerbuijk (V) – Läkemedelsverket
Common notifications from GMP inspection of ATMP: Lisa Lundkvist (V) – Läkemedelsverket
GCP inspection of ATMP clinical trials: Inger Ekman (V) – Läkemedelsverket

Introduction: Lindsay Davies, Leo Groenewegen
Pitches
- Evaluating potency in ATMPs with FluoroSpot: Ellen Einarsson – Mabtech
- Auto-antibody biomarkers: Fredrik Sundberg (V) – Sengenics
Rapid sterility testing: Jesper Ericsson – Symcel
Potency assays for cell based ATMPs – from Phase 1 to Commercial: Therese Choquette – Tigen Pharma

FIH hESC derived dopaminergic neuron progenitors for Parkinson’s disease: Malin Parmar – Lund University

AI based QC methods for ATMP manufacturing: Jane Synnergren – University of Skövde
hPSC derived human ventricular progenitor cells: Ricardo Baptista – SmartCella
Advances in hiPSC derived NK cells: Kalle Malmberg – Karolinska Institutet
Strategies for immune evasion in hPSC derived cellular therapies: Evren Alici – Karolinska Institutet
AdBIOPRO to developing novel scalable manufacturing solutions: Veronique Chotteau – AdBIOPRO and KTH

ATMP challenges in hospital pharmacy roles – clinical trial v market approved products: Heidi Ekelund – Sahlgrenska
Implementing AAV based gene therapy: Petra Gabric Toplican (V) – KUH
The overall picture of implementation in healthcare: Ana Carneiro – Skåne University Hospital Comprehensive Cancer Centre
Adapting transfusion medicine to gene therapies for genetic disease and cancer: Josefina Dykes – SUS

Commemoration of Jukka Lausmaa: Jim Lund – CCRM Nordic
Wrap up ATMP2030: Jennifer Rosendahl – Project leader ATMP2030
Wrap up CAMP: Paul Kingham – CAMP Coordinator
ATMP Sweden platforms: Heather Main – Project Manager ATMP Sweden
Föreningen ATMP Sweden: Agneta Edberg – Chair fATMP Sweden
Samordningsfunktion: Dag Larsson – Steering group Chair Samordningsfunktion
Future proofing national synergy in Swedish ATMP (Panel Discussion): Mikael Wiberg – Chair CAMP Board, Agneta Edberg, Dag Larsson, Hannah Karlsson – ATMP Centre Network

Introduction to AAV therapy, Use in Sweden and challenges for clinical manufacture: Annika Ericsson – CombiGene
Rationally designed AAV vectors for cell specific targeting: Patrick Aldrin-Kirk – rAAVen Therapeutics

Gender aspects in the Nordic ATMP Space 2023: Stephanie Mattsson – CCRM Nordic
The benefits of diversity in a team and challenges in establishing diversity: Sarah Lidé – VILDA
The academic perspective: Darcy Wagner – Lund University
Panel Discussion with additional panelists (Sarah Callens, Henrik Moller Thomsen – Miltenyi Biotec, Kylie Foo Thams – SmartCella Solutions)

In Vivo Dendritic Cell Reprogramming for Cancer Immunotherapy: Filipe Pereira – Lund Stem Cell Centre
Towards clinical trials with human intestinal organoids: Kim Jensen – Copenhagen University, ReNew

Competence needs and training within ATMP: Paul Kingham – ATMP2030 project
Regenerative medicine workforce gap analysis in Denmark: Isabella Samuelson – Novo Nordisk Foundation
Scaling up cooperation in ATMP education: Niels Geijsen – Leiden University Medical Centre
Panel discussion with additional panelist: Niels B. Larsen – DTU Health Tech and Johan Flygare – Lund University